|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
JP2000505068A
(ja)
|
1996-03-13 |
2000-04-25 |
トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア |
補体活性化を阻害する新規ペプチド類
|
|
WO1998055471A1
(en)
|
1997-06-03 |
1998-12-10 |
Biocryst Pharmaceuticals, Inc. |
Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
|
|
NZ507760A
(en)
|
1998-03-26 |
2002-10-25 |
Japan Tobacco Inc |
Amide derivatives and nociceptin antagonists
|
|
CZ297264B6
(cs)
|
1998-09-09 |
2006-10-11 |
Metabasis Therapeutics, Inc. |
Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
|
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
|
WO2001017980A1
(en)
|
1999-09-03 |
2001-03-15 |
Ajinomoto Co., Inc. |
Novel processes for preparing oxazepine derivatives
|
|
US7528165B2
(en)
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
CN100354276C
(zh)
|
2002-07-16 |
2007-12-12 |
阿姆拉医疗有限公司 |
生物活性化合物
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
US7989589B2
(en)
|
2002-09-20 |
2011-08-02 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved activity
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
EP1567487A4
(en)
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
|
|
AU2003902946A0
(en)
|
2003-06-12 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
BRPI0506629A
(pt)
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
EP1727811B1
(en)
|
2004-03-24 |
2014-11-12 |
Shire Orphan Therapies GmbH |
New compounds for the inhibition of angiogenesis and use of thereof
|
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
ES2390828T3
(es)
|
2005-11-28 |
2012-11-16 |
The Trustees Of The University Of Pennsylvania |
Análogos potentes de la compstatina
|
|
BRPI0619733A2
(pt)
|
2005-12-12 |
2011-10-11 |
Genelabs Tech Inc |
compostos antivirais de n-(anel aromático de 6 membros)-amido
|
|
HUE066795T2
(hu)
|
2006-03-15 |
2024-09-28 |
Alexion Pharma Inc |
Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
|
|
JPWO2008047831A1
(ja)
|
2006-10-17 |
2010-02-25 |
協和発酵キリン株式会社 |
Ｊａｋ阻害剤
|
|
CN101583598B
(zh)
|
2007-01-15 |
2012-09-12 |
参天制药株式会社 |
具有IκB激酶β抑制活性的新型吲哚衍生物
|
|
EP2148691B1
(en)
|
2007-02-05 |
2015-05-20 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
|
|
CN101910177B
(zh)
|
2007-12-24 |
2013-08-28 |
泰博特克药品公司 |
作为丙型肝炎病毒抑制剂的大环吲哚
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
GB2469471B
(en)
|
2009-04-14 |
2015-01-14 |
Skype |
Optimising communications
|
|
CA2760839C
(en)
|
2009-05-01 |
2019-02-12 |
The Trustees Of The University Of Pennsylvania |
Modified compstatin with peptide backbone and c-terminal modifications
|
|
US9291622B2
(en)
|
2009-05-21 |
2016-03-22 |
Apellis Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
CA2777013A1
(en)
|
2009-10-16 |
2011-04-21 |
Mochida Pharmaceutical Co., Ltd. |
Marker associated with non-alcoholic steatohepatitis
|
|
CN102958535A
(zh)
|
2009-11-05 |
2013-03-06 |
亚力史剑桥公司 |
阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
|
|
PT3511330T
(pt)
|
2009-12-31 |
2020-12-24 |
Hutchison Medipharma Ltd |
Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
|
|
ES2734552T3
(es)
|
2010-04-16 |
2019-12-10 |
Ac Immune Sa |
Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide
|
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
WO2012006599A2
(en)
|
2010-07-09 |
2012-01-12 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
|
CN103402996B
(zh)
|
2011-01-04 |
2015-02-11 |
诺瓦提斯公司 |
可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
|
|
RU2653439C9
(ru)
|
2011-05-11 |
2018-10-16 |
Апеллис Фармасьютикалс, Инк. |
Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
|
|
RS55123B1
(sr)
|
2011-05-27 |
2016-12-30 |
Achillion Pharmaceuticals Inc |
Supstituisani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za lečenje infekcija hepatitis c virusa
|
|
EP2739144A4
(en)
|
2011-06-20 |
2015-04-01 |
Alzheimer S Inst Of America Inc |
COMPOUNDS AND ITS THERAPEUTIC USE
|
|
CA2840270C
(en)
|
2011-06-22 |
2023-09-26 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US20130035392A1
(en)
|
2011-08-01 |
2013-02-07 |
Mcgeer Patrick L |
Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
|
|
PL2753636T3
(pl)
|
2011-09-07 |
2020-05-18 |
The Trustees Of The University Of Pennsylvania |
Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
|
|
CN111700878A
(zh)
|
2012-05-03 |
2020-09-25 |
卡拉制药公司 |
显示提高的粘膜转移的药物纳米粒子
|
|
SG11201406973PA
(en)
|
2012-05-04 |
2014-12-30 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
US9056874B2
(en)
|
2012-05-04 |
2015-06-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
PT2861246T
(pt)
|
2012-06-18 |
2021-04-05 |
Univ Leicester |
Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
|
|
CA2877526A1
(en)
|
2012-06-20 |
2013-12-27 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
CN104619698B
(zh)
|
2012-06-28 |
2016-08-31 |
诺华股份有限公司 |
吡咯烷衍生物及其作为补体途径调节剂的用途
|
|
JP6209605B2
(ja)
|
2012-06-28 |
2017-10-04 |
ノバルティス アーゲー |
ピロリジン誘導体、および補体経路調節因子としてのその使用
|
|
US20150191462A1
(en)
|
2012-06-28 |
2015-07-09 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
WO2014002051A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
EP2867229B1
(en)
|
2012-06-28 |
2017-07-26 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
CN104640855B
(zh)
|
2012-06-28 |
2017-08-29 |
诺华股份有限公司 |
补体途经调节剂及其用途
|
|
ITMI20121156A1
(it)
|
2012-06-29 |
2013-12-30 |
Consiglio Nazionale Ricerche |
Metodo di elaborazione di immagini di tomografia a coerenza ottica
|
|
WO2014005150A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
|
|
WO2014002059A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
|
|
US9550755B2
(en)
|
2012-07-12 |
2017-01-24 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
CA2881322A1
(en)
|
2012-09-10 |
2014-03-13 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2014078734A2
(en)
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
US10035822B2
(en)
|
2012-11-15 |
2018-07-31 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
US9773428B2
(en)
|
2012-12-11 |
2017-09-26 |
Fluidity Software, Inc. |
Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
|
|
CA2899034A1
(en)
|
2013-01-23 |
2014-07-31 |
Musc Foundation For Research Development |
Targeting constructs based on natural antibodies and uses thereof
|
|
US9475806B2
(en)
|
2013-03-14 |
2016-10-25 |
Novartis Ag |
Complement factor B inhibitors and uses there of
|
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
CN105555766A
(zh)
|
2013-07-18 |
2016-05-04 |
诺华股份有限公司 |
作为补体因子d抑制剂的氨基甲基-联芳基衍生物及其应用
|
|
JP2016169161A
(ja)
|
2013-07-19 |
2016-09-23 |
大日本住友製薬株式会社 |
新規イミダゾピリジン化合物
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
US20150104445A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
|
EP3089963A1
(en)
|
2013-10-30 |
2016-11-09 |
Novartis AG |
2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
|
|
EP3110419A4
(en)
|
2014-02-25 |
2017-07-26 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of complement mediated disorders
|
|
WO2016088082A1
(en)
|
2014-12-05 |
2016-06-09 |
Novartis Ag |
Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
|
WO2017035348A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of medical disorders
|
|
WO2017035413A2
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
|
|
WO2017035355A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
|
WO2017035352A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of medical disorders
|
|
US10000516B2
(en)
|
2015-08-26 |
2018-06-19 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
|
WO2017035411A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of immune and inflammatory disorders
|
|
WO2017035418A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for treatment of immune and inflammatory disorders
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
|
WO2017035415A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of immune and inflammatory disorders
|
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
|
WO2017035417A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of immune and inflammatory disorders
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
WO2017098328A2
(en)
|
2015-12-11 |
2017-06-15 |
Lifesci Phamaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
SG11201805828YA
(en)
|
2016-01-14 |
2018-08-30 |
Chemocentryx Inc |
Method of treating c3 glomerulopathy
|
|
EP3405577B8
(en)
|
2016-01-20 |
2023-02-15 |
396419 B.C. Ltd. |
Compositions and methods for inhibiting factor d
|
|
TWI747873B
(zh)
|
2016-02-01 |
2021-12-01 |
美商百歐克斯製藥公司 |
苯并吡唑化合物及其類似物
|
|
MX2018016046A
(es)
|
2016-06-27 |
2019-05-02 |
Achillion Pharmaceuticals Inc |
Quinazolina y compuestos indol para tratar trastornos medicos.
|
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
|
WO2018160892A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for treatment of medical disorders
|
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
|
CA3053818A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
|
WO2019028284A1
(en)
|
2017-08-02 |
2019-02-07 |
Achillion Pharmaceuticals, Inc. |
THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
|
|
MX2020003619A
(es)
|
2017-10-04 |
2020-10-28 |
Alexion Pharma Inc |
Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
WO2020069024A1
(en)
|
2018-09-25 |
2020-04-02 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
|
CN113195472A
(zh)
|
2018-12-17 |
2021-07-30 |
艾其林医药公司 |
用于治疗补体介导的病症的靶向给药
|